SI2054066T1 - Postopki za zdravljenje radiacijskega enteritisa - Google Patents

Postopki za zdravljenje radiacijskega enteritisa

Info

Publication number
SI2054066T1
SI2054066T1 SI200731674T SI200731674T SI2054066T1 SI 2054066 T1 SI2054066 T1 SI 2054066T1 SI 200731674 T SI200731674 T SI 200731674T SI 200731674 T SI200731674 T SI 200731674T SI 2054066 T1 SI2054066 T1 SI 2054066T1
Authority
SI
Slovenia
Prior art keywords
treatment
methods
radiation enteritis
enteritis
radiation
Prior art date
Application number
SI200731674T
Other languages
English (en)
Inventor
Doug Bettenhausen
Christopher Jahraus
Original Assignee
Salix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals, Inc. filed Critical Salix Pharmaceuticals, Inc.
Publication of SI2054066T1 publication Critical patent/SI2054066T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
SI200731674T 2006-08-02 2007-08-02 Postopki za zdravljenje radiacijskega enteritisa SI2054066T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83527306P 2006-08-02 2006-08-02
US85029906P 2006-10-06 2006-10-06
PCT/US2007/017379 WO2008016708A2 (en) 2006-08-02 2007-08-02 Methods for treatment of radiation enteritis
EP07836488.2A EP2054066B1 (en) 2006-08-02 2007-08-02 Methods for treatment of radiation enteritis

Publications (1)

Publication Number Publication Date
SI2054066T1 true SI2054066T1 (sl) 2015-08-31

Family

ID=38997731

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731674T SI2054066T1 (sl) 2006-08-02 2007-08-02 Postopki za zdravljenje radiacijskega enteritisa

Country Status (17)

Country Link
EP (1) EP2054066B1 (sl)
JP (3) JP5844961B2 (sl)
KR (2) KR20150132214A (sl)
CN (1) CN104382900A (sl)
AU (1) AU2007281413B2 (sl)
BR (1) BRPI0714724A8 (sl)
CA (1) CA2659874C (sl)
DK (1) DK2054066T3 (sl)
ES (1) ES2538478T3 (sl)
HK (1) HK1130199A1 (sl)
HU (1) HUE025306T2 (sl)
IL (1) IL196843A (sl)
MX (1) MX2009001342A (sl)
PL (1) PL2054066T3 (sl)
PT (1) PT2054066E (sl)
SI (1) SI2054066T1 (sl)
WO (1) WO2008016708A2 (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP5844961B2 (ja) * 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
HUE065491T2 (hu) 2008-10-02 2024-05-28 Salix Pharmaceuticals Ltd A hepatikus enkefalopátia kezelése rifaximin alkalmazásával
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
EP2396652B1 (en) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
US20110294726A1 (en) * 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
CN105477624A (zh) * 2015-12-16 2016-04-13 官键 一种用于治疗放射性直肠炎的药物组合物
RU2618452C1 (ru) * 2015-12-28 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования энтерита

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
JP5844961B2 (ja) * 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法

Also Published As

Publication number Publication date
AU2007281413A1 (en) 2008-02-07
HK1130199A1 (en) 2009-12-24
PT2054066E (pt) 2015-07-16
JP2016028079A (ja) 2016-02-25
WO2008016708A2 (en) 2008-02-07
IL196843A0 (en) 2009-11-18
CA2659874C (en) 2016-10-11
BRPI0714724A8 (pt) 2018-04-10
CN104382900A (zh) 2015-03-04
BRPI0714724A2 (pt) 2015-07-07
KR20150132214A (ko) 2015-11-25
EP2054066A2 (en) 2009-05-06
JP2009545602A (ja) 2009-12-24
EP2054066A4 (en) 2011-01-05
ES2538478T3 (es) 2015-06-22
JP5844961B2 (ja) 2016-01-20
IL196843A (en) 2016-03-31
DK2054066T3 (en) 2015-06-08
HUE025306T2 (hu) 2016-01-28
EP2054066B1 (en) 2015-04-15
JP2013227350A (ja) 2013-11-07
PL2054066T3 (pl) 2015-12-31
JP5993074B2 (ja) 2016-09-14
MX2009001342A (es) 2009-08-31
WO2008016708A3 (en) 2008-06-19
AU2007281413B2 (en) 2013-10-31
KR20090047490A (ko) 2009-05-12
CA2659874A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
EP2054066A4 (en) METHOD FOR TREATING RADIATION ENTITY
IL248204A0 (en) Combined treatment of tumors expressing 38cd
HK1156631A1 (en) Novel compounds and methods for therapy
EP2032131A4 (en) Methods of Treatment
IL197315A0 (en) Treatment of cancer
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
EP1991230A4 (en) METHOD FOR THE TREATMENT OF CANCER
GB0610746D0 (en) Method of treatment
EP2068865A4 (en) METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT
IL199689A0 (en) Compounds and method for treatment of cancer
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
EP2029156A4 (en) POLY THERAPY FOR TREATING CANCER
EP2225226A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
EP2088862A4 (en) METHOD OF TREATING CANCER
GB0708452D0 (en) Treatment of nuclear studge
EP1986656A4 (en) WITHACNISTINE COMPOUNDS FOR THE TREATMENT OF CANCER
EP2164494A4 (en) Methods of Treatment
IL226363A0 (en) Compounds and methods for treating cancer
EP2214485A4 (en) METHOD FOR THE TREATMENT OF CANCER
HK1209754A1 (en) Compounds and methods for the treatment of cancer
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
EP2203432A4 (en) PROCESSING METHOD
GB0600903D0 (en) Treatment of cancer
IL196361A0 (en) Combination methods of treating cancer
GB0717337D0 (en) Method of treatment